Showing results (11-20 of 104) with videos related to
Sort By:
Pageof 11
Cancer|September 15, 1984
Dosing and sequencing for antineoplastic synergism in combination chemotherapyA GoldinCancer Chemotherapy and Pharmacology|January 1, 1981
Absence of delayed lethality in mice treated with aclacinomycin AT H Corbett, D P Griswold, B J Roberts, et al.Cancer Treatment Reports|May 1, 1978
Comparative antitumor activity of actinomycin analogs in mice bearing Ridgway osteogenic sarcoma or P388 leukemiaW C Rose, M W Trader, W R Laster, et al.Cancer Research|October 1, 1980
Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinaseR W Brockman, Y C Cheng, F M Schabel, et al.Antibiotics and Chemotherapy|January 1, 1978
Chemotherapy modalities and immune condition of the hostA Goldin, D P HouchensUrology|January 1, 1978
Intra-arterial streptokinase and renal artery embolizationC J Sanfelippo, A GoldinAntimicrobial Agents and Chemotherapy|October 1, 1980
Erythro-9-(2-hydroxy-3-nonyl) Adenine alone and in combination with 9-beta-D-arabinofuranosyladenine in treatment of systemic herpesvirus infections in miceW M Shannon, G Arnett, F M Schabel, et al.Cancer Treatment Reports|September 11, 1976
Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNUF M Schabel, M W Trader, W R Laster, et al.Cancer Treatment Reports|September 1, 1979
cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of miceF M Schabel, M W Trader, W R Laster, et al.Pageof 11